Drugs / Intravenous human immunoglobulin
Intravenous human immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02219165 | Jan 2015 → Apr 2019 | toxic shock syndrome | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous human immunoglobulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02219165 ↗ |
| Action | Inhibit | “IVIG are able to neutralize their toxicity” NCT02219165 ↗ |
| Modality | Protein / enzyme biologic | “Intravenous human immunoglobulin” NCT02219165 ↗ |
| Route | Intravenous | “Intravenous human immunoglobulin” NCT02219165 ↗ |